AlphaMark Advisors LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)

AlphaMark Advisors LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,350 shares of the company’s stock after purchasing an additional 200 shares during the period. AlphaMark Advisors LLC’s holdings in Novo Nordisk A/S were worth $288,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Raymond James & Associates grew its position in Novo Nordisk A/S by 1.0% during the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after buying an additional 36,223 shares during the period. Natixis Advisors LLC increased its stake in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares in the last quarter. International Assets Investment Management LLC raised its position in shares of Novo Nordisk A/S by 10,608.4% during the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. LPL Financial LLC grew its holdings in Novo Nordisk A/S by 3.6% during the 3rd quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock valued at $162,266,000 after buying an additional 47,496 shares during the last quarter. Finally, Mediolanum International Funds Ltd purchased a new position in Novo Nordisk A/S during the third quarter worth $98,765,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the topic of a number of analyst reports. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $87.94 on Friday. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a 50 day moving average price of $95.35 and a 200 day moving average price of $115.17. The company has a market cap of $394.65 billion, a price-to-earnings ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.